International Journal of Interdisciplinary Innovative Research & Development (IJIIRD)
ISSN: 2456-236X
Vol. 11 Special Issue 02 | 2026

Brain Tumor Detection Using Medical Images: A Deep Learning Review

Mr. Lalitkumar Tayade[1] Mr. Sudesh L. Farpat[2]
[1] Student, Computer Science and Engineering, Padm. Dr. VBKCOE, Malkapur Maharashtra, India
[2] Head of Department, Computer Science and Engineering, Padm. Dr. VBKCOE, Malkapur Maharashtra, India

DOI: 10.5281/zenodo.19287019

ABSTRACT

Brain tumors are among the most critical neurological disorders, contributing significantly to morbidity and mortality worldwide. They result from abnormal and uncontrolled growth of brain cells and are broadly classified into primary tumors, originating in the brain, and secondary (metastatic) tumors, which spread from other organs. Common primary brain tumors include gliomas, meningiomas, and pituitary tumors, each varying in aggressiveness, location, and prognosis. Early and accurate diagnosis is essential, as timely intervention through surgery, radiotherapy, or chemotherapy can significantly improve patient outcomes, whereas delayed or inaccurate detection may lead to tumor progression, neurological deficits, and reduced survival rates.

Medical imaging plays a pivotal role in brain tumor detection, providing non-invasive visualization of tumor location, size, and structure. Magnetic Resonance Imaging (MRI) is the preferred modality due to its high soft-tissue contrast and capability to generate multiple sequences such as T1, T2, FLAIR, and contrast-enhanced scans, which aid in distinguishing tumor boundaries and surrounding edema. Computed Tomography (CT) is often used in emergency settings for rapid assessment, particularly for detecting hemorrhages and calcifications, while Positron Emission Tomography (PET) offers functional information by highlighting tumor metabolism, useful in differentiating benign and malignant lesions. Multi-modal imaging, combining anatomical and functional data, has further improved diagnostic accuracy.

In recent years, deep learning (DL) has revolutionized medical image analysis for brain tumor detection. Convolutional Neural Networks (CNNs) automatically learn hierarchical features from imaging data, enabling precise classification, segmentation, and progression prediction. Hybrid models integrating CNNs with attention mechanisms or recurrent networks have further enhanced performance, especially for multi-modal and 3D imaging. This review examines the state-of-the-art deep learning approaches for brain tumor detection, including CNN-based architectures, hybrid models, datasets, challenges, and future research directions, highlighting their potential to improve diagnostic accuracy and clinical decision-making.

1. INTRODUCTION

Brain tumors arise from abnormal and uncontrolled growth of brain cells and are classified into primary tumors, originating within the brain, and secondary (metastatic) tumors, which spread from other organs. Among the most common types are gliomas, meningiomas, and pituitary tumors, each differing in growth rate, location, and severity. Traditional diagnosis relies on radiologists' visual assessment of medical imaging scans, such as MRI or CT, a process that is often time-consuming, subjective, and prone to human error.

Recent advances in deep learning (DL), particularly Convolutional Neural Networks (CNNs), have revolutionized brain tumor detection. CNNs automatically extract hierarchical features directly from raw images, eliminating the need for handcrafted features required in conventional machine learning methods. This enables more accurate and robust detection, classification, and segmentation of tumors. Hybrid architectures incorporating attention mechanisms, recurrent networks, or transformers have further enhanced performance, particularly for multi-modal and 3D imaging.

The growing availability of large-scale annotated medical imaging datasets, combined with advances in GPU computing, has accelerated research and facilitated the development of clinically viable computer-aided diagnosis (CAD) systems. These systems hold promise for improving diagnostic efficiency, reducing human error, and supporting early intervention, ultimately enhancing patient outcomes in brain tumor management.

2. MEDICAL IMAGING MODALITIES

Accurate brain tumor detection depends on the quality and type of medical images used.

2.1 Magnetic Resonance Imaging (MRI)

MRI is the most widely used modality due to its high soft-tissue contrast. Common sequences include:

- **T1-weighted:** Good anatomical detail.
- **T2-weighted:** Highlights edema and lesions.
- **FLAIR (Fluid-Attenuated Inversion Recovery):** Suppresses CSF signals for better lesion visibility.
- **T1c (Contrast-enhanced):** Highlights tumor boundaries.

MRI is particularly preferred for brain tumor segmentation and classification because it reveals subtle tissue differences.

2.2 Computed Tomography (CT)

CT imaging is faster and more widely available, commonly used in emergency settings. It is less sensitive than MRI for soft tissues but effective in detecting calcifications, hemorrhages, or bone involvement.

2.3 Positron Emission Tomography (PET)

PET scans measure metabolic activity, providing functional insights that complement structural imaging. PET-MRI fusion has shown promise in better tumor characterization.

Table 1: Comparison of Brain Imaging Modalities

Modality	Strengths	Limitations
MRI	High soft-tissue contrast	Expensive, slow
CT	Fast, widely available	Poor soft-tissue contrast
PET	Functional/metabolic data	Low spatial resolution

3. DEEP LEARNING APPROACHES

Deep learning methods have shown exceptional performance in brain tumor detection, often surpassing traditional machine learning techniques.

3.1 Convolutional Neural Networks (CNNs)

CNNs are the most widely used architecture due to their ability to automatically learn spatial features. Key tasks include:

- **Tumor classification:** Differentiating benign vs malignant tumors.
- **Segmentation:** Delineating tumor regions for treatment planning.
- **Multi-class tumor detection:** Identifying gliomas, meningiomas, and pituitary tumors.

Popular architectures: AlexNet, VGGNet, ResNet, DenseNet, and U-Net (for segmentation).

3.2 Recurrent Neural Networks (RNNs)

RNNs, especially LSTMs, are employed when temporal or sequential information is relevant. In 3D MRI analysis, RNNs can integrate information across slices for improved segmentation.

3.3 Hybrid Models

Combining CNNs with attention mechanisms, Transformers, or RNNs improves detection accuracy, particularly for multi-modal data fusion (MRI + PET).



Figure 1: Typical CNN-based framework for brain tumor detection

4. DATASETS

Availability of quality datasets is critical for deep learning model training and validation. Common datasets include:

- **BraTS (Brain Tumor Segmentation Challenge):** Multi-modal MRI data with annotated glioma regions.
- **Figshare Dataset:** MRI images for glioma, meningioma, and pituitary tumors.
- **TCIA (The Cancer Imaging Archive):** Multi-institutional imaging datasets.
- **OASIS and REMBRANDT:** MRI collections used for research in brain tumors.

Table 2: Popular Brain Tumor Datasets

Dataset	**Modalities**	**Size**	**Purpose**
BraTS	MRI (T1, T1c, T2, FLAIR)	400+ cases	Segmentation, classification
Figshare	MRI	3064 images	Classification
TCIA	MRI, CT	1000+ scans	Multi-modal analysis

5. PERFORMANCE METRICS

Deep learning models are evaluated using metrics appropriate to classification or segmentation tasks:

- **Classification:** Accuracy, precision, recall, F1-score, AUC-ROC.
- **Segmentation:** Dice coefficient, Intersection over Union (IoU), volumetric similarity.
  Figure 2: Example segmentation output using U-Net on MRI showing tumor region (highlighted in red).

6. CHALLENGES

Despite advancements, several challenges persist:

1. **Data Scarcity:** Annotated medical images are limited due to privacy concerns and high labeling costs.
2. **Tumor Heterogeneity:** Tumors vary in size, shape, location, and intensity across patients.
3. **Noise and Artifacts:** Imaging artifacts and variability in acquisition protocols affect model performance.
4. **Computational Cost:** 3D models require significant GPU resources.
5. **Generalization:** Models trained on one dataset may perform poorly on data from different institutions.

7. FUTURE DIRECTIONS

- **Lightweight and Real-time Models:** Deployment in clinical settings demands computationally efficient models.
- **Multi-modal Fusion:** Integrating MRI, PET, and CT data can improve accuracy.
- **Explainable AI:** Increasing trust among clinicians by making model predictions interpretable.
- **Semi-supervised and Unsupervised Learning:** Reducing dependency on large labeled datasets.
- **Integration with Treatment Planning:** Combining tumor detection with therapy guidance and prognosis prediction.

8. CONCLUSION

Deep learning has revolutionized brain tumor detection and classification using medical images. CNN-based architectures, particularly U-Net for segmentation, demonstrate high accuracy and robustness. Challenges such as data scarcity, tumor heterogeneity, and model generalization remain. Future research focusing on multi-modal data, explainable AI, and real-time deployment is essential to translate deep learning models into routine clinical practice.

9. REFERENCES

[1] Menze, B. H., et al. “The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS).” IEEE Transactions on Medical Imaging, 2015.

[2] Pereira, S., et al. “Brain Tumor Segmentation Using Convolutional Neural Networks in MRI Images.” IEEE Transactions on Medical Imaging, 2016.

[3] Cheng, J., et al. “Enhanced Performance of Brain Tumor Classification via CNNs.” Journal of Digital Imaging, 2017.

[4] Bakas, S., et al. “The Cancer Imaging Archive (TCIA) Collection of Brain MRI Data.” Scientific Data, 2017.

[5] Zhou, Z., et al. “UNet++: Redesigning Skip Connections for Medical Image Segmentation.” Medical Image Analysis, 2018.

[6] Naeem Ullah,Javed Ali Khan, etc. “An Effective Approach to Detect and Identify Brain Tumors Using Transfer Learning” , Advanced Decision Making in Clinical Medicine , Appl. Sci. 2022, 12(11), 5645